Glimepiride 1 / 2mg + Pioglitazone 15mg + Metformin (SR) 500mg tablets
Glimepiride A third generation sulphonylurea, which reduces blood glucose by inducing islet cells of the pancreas to secrete insulin. Glimepiride also has other beneficial effects on metabolism.
Pioglitazone is a thiazolidinedione anti-diabetic agent that decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Unlike sulphonylureas, pioglitazone is not an insulin secretagogue. Pioglitazone is a potent and highly selective agonist for peroxisome proliferator-activated receptor-γ (PPAR-γ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle and liver. Activation of PPAR-γ receptors, modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. It also has a partial alpha agonist property which has a positive effect on lipid regulation and makes it superior to Rosiglitazone.
Metformin is an oral anti-hyperglycemic drug, used to improve glucose tolerance in patients with type II diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
